Dermata Therapeutics, Inc. (DRMA): auditor change — Dermata Therapeutics dismisses Baker Tilly, appoints CBIZ CPAs as new auditor

Dermata Therapeutics, Inc.

Baker Tilly dismissed as independent auditor effective January 31, 2026.
CBIZ CPAs (formerly Mayer Hoffman McCann) appointed February 2, 2026.
No disagreements with Baker Tilly on accounting principles or disclosures.
Baker Tilly's prior reports included a going-concern explanatory paragraph.
CBIZ CPAs previously served as Dermata's auditor from 2016 to 2023.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Dermata Therapeutics, Inc. dismissed Baker Tilly US, LLP as its auditor.

Action: dismissal
Auditor: Baker Tilly US, LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On January 30, 2026, Dermata Therapeutics, Inc. (the “Company”) notified Baker Tilly US, LLP (formerly Moss Adams LLP) (“Baker Tilly”) that Baker Tilly would be dismissed as the Company’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Dermata Therapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

On February 2, 2026, the Audit Committee approved the appointment of CBIZ CPAs P.C., (formerly known as Mayer Hoffman McCann P.C.) (“CBIZ CPAs”) as the Company’s new independent registered public accounting firm.

View on SEC.gov

Browse all auditor changes →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-004905

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.